The Government, through IDA Ireland, is supporting the investment.

The new funds will enable Boston Scientific to expand its R&D and technical capabilities regarding the design of its next-generation cardiac rhythm management devices manufactured at the Clonmel facility.

Enterprise Minister Richard Bruton said such investments not only create high-value jobs but also provide spin-off benefits for Irish businesses, researchers and the Irish economy.

Brad Sorenson, vice-president of operations for Boston Scientific, said the funding will benefit the company’s cariology, rhythm and vascular group by enhancing its ability to provide R&D, design and manufacturing support for its medical device technologies.

“I am confident that, with the talent and expertise of our Clonmel staff, we can continue to successfully commercialise new life-saving innovations for our customers and their patients worldwide,” Sorenson said.

In Ireland, Boston Scientific also has campuses in Clonmel, Galway and Cork.